This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RUFUS - Group Rumination-focused CBT for Negative Symptoms (RUFUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05851950
Recruitment Status : Recruiting
First Posted : May 10, 2023
Last Update Posted : October 23, 2023
Sponsor:
Information provided by (Responsible Party):
Mental Health Services in the Capital Region, Denmark

Brief Summary:

Abstract - --

Introduction:

Psychosis spectrum disorders are characterized by both positive and negative symptoms, but whereas there is good effect of treatment on positive symptoms, there is still a scarcity of effective interventions aimed at reducing negative symptoms. Rumination has been proposed as an important and fundamental factor in the development and maintenance of symptoms across psychiatric diagnoses, and there is a need to develop effective interventions targeting rumination behaviors and negative symptoms in patients with psychotic disorders. The aim of the current study is to investigate the feasibility and acceptability of group rumination-focused cognitive behavioral therapy (RFCBT) in the treatment of young people with psychosis spectrum disorders as well as investigating potential indications of treatment efficacy.

Methods and analysis: The study is a mixed-method clinical randomized controlled pilot trial with a target sample of 60 patients, who are randomized to either receive 13 weeks of group CFCBT or 13 weeks of treatment as usual (TAU). All patients are examined at the start of the project and at the 13-week follow-up. The researcher will compare changes in outcomes from baseline to posttreatment between group CFCBT and TAU. In addition, qualitative analyzes are carried out to explore feasibility and acceptability and to uncover the patients' experience of receiving the intervention.


Condition or disease Intervention/treatment Phase
Psychotic Disorders Other: group rumination focused cognitive behavioural therapy Other: Treatment as usual Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: RUFUS - a Randomized Mixed Methods Pilot Clinical Trial Investigating the Relevance and Feasibility of Rumination-focused Cognitive Behavioral Therapy in the Treatment of Patients With Emergent Psychosis Spectrum Disorder
Actual Study Start Date : August 1, 2023
Estimated Primary Completion Date : January 31, 2025
Estimated Study Completion Date : July 1, 2026


Arm Intervention/treatment
Experimental: rumination-focused cognitive behavioural group therapy
1 individual in-take session, 11 sessions of rumination-focused cognitive behavioural group therapy, 1 individual closing session.
Other: group rumination focused cognitive behavioural therapy
Psychotherapy

Active Comparator: Treatment as usual
standard OPUS treatment. OPUS treatment is handled by an interdisciplinary OPUS team and consists primarily of medical treatment, psychoeducation, training in symptom management and social skills as well as family discussions. All patients in OPUS have a contact doctor and a contact person who is responsible for coordinating the treatment and collaborating with municipal bodies.
Other: Treatment as usual
opus treatment




Primary Outcome Measures :
  1. the Brief Negative Symptoms Scale (BNSS) [ Time Frame: up to 20 weeks ]
    Assessment of negative symptoms on a scale from 0-78


Secondary Outcome Measures :
  1. Perseverative Thinking Questionnaire (PTQ) [ Time Frame: up to 20 weeks ]
    Measuring frequency of rumination. Resulting in a total score of 0-60.

  2. Ruminative Response Scale (RRS) [ Time Frame: up to 20 weeks ]
    Measuring levels of rumination in relation to depression. Resulting in a total score of 22-88.

  3. Social Functioning Scale (SFS) [ Time Frame: up to 20 weeks ]
    Measuring level of functioning on a scale from of 0-228

  4. Scale for the assessment of positive symptoms (SAPS) [ Time Frame: up to 20 weeks ]
    Measuring presence of positive symptoms on a scale from 0-170

  5. Calgary depression scale (CDS) [ Time Frame: up to 20 weeks ]
    Measuring depressive symptoms on a scale from 0-27

  6. Behavior Rating Inventory of Executive Function (BRIEF) [ Time Frame: up to 20 weeks ]
    Measuring executive functioning on a scale from 75-225



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 37 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosed with a psychosis spectrum disorder (ICD-10 F2x)
  2. At least 8 months left of their OPUS treatment
  3. The presence of rumination behavior as assessed by a score of minimum 30 on the Perseverative Thinking Questionnaire (PTQ)
  4. Danish-speaking

Exclusion Criteria:

  1. Substance abuse or positive symptoms that make participation in therapy difficult
  2. Severe suicidal thoughts/behavior
  3. Lacks capacity to consent
  4. Mild, moderate, or severe intellectual disability (IQ ˂ 70)
  5. Planned adjustment of antidepressant and/or antipsychotic treatment (noted in the patient's medical record)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05851950


Contacts
Layout table for location contacts
Contact: Lars Clemmensen 23492490 lars.clemmensen@regionh.dk

Locations
Layout table for location information
Denmark
Mental Health Centre Copenhagen Recruiting
Copenhagen, Denmark
Contact: Christin Lund       christin.louise.nymann.lund@regionh.dk   
Sponsors and Collaborators
Mental Health Services in the Capital Region, Denmark
Investigators
Layout table for investigator information
Principal Investigator: Louise B Glenthøj Mental health center of Copenhagen
Layout table for additonal information
Responsible Party: Mental Health Services in the Capital Region, Denmark
ClinicalTrials.gov Identifier: NCT05851950    
Other Study ID Numbers: 05851950
First Posted: May 10, 2023    Key Record Dates
Last Update Posted: October 23, 2023
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psychotic Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders